pvi.peerview.com
Open in
urlscan Pro
84.207.240.206
Public Scan
Submitted URL: https://click.email.peerviewpress.com/?qs=740bda3779b8e5647b5c81f7eae945c91488329dcafaaa2ac0155dd8aefa6ab6b763fa584a7737da0a93e3a43f93...
Effective URL: http://pvi.peerview.com/wix/23/p615098493.aspx
Submission: On December 28 via manual from US — Scanned from DE
Effective URL: http://pvi.peerview.com/wix/23/p615098493.aspx
Submission: On December 28 via manual from US — Scanned from DE
Form analysis 1 forms found in the DOM
Name: ctlform — POST /wix/23/p615098493.aspx
<form action="/wix/23/p615098493.aspx" method="post" novalidate="novalidate" class="ctlform" id="ctlform" name="ctlform">
<div>
<input type="hidden" name="__state" value="456">
<input type="hidden" name="r" value="300">
<input type="hidden" name="__seqno" value="0">
<input type="hidden" name="s" value="DKLSTCYP">
<input type="hidden" name="__version" value="12">
<input type="hidden" name="__prevPageProgress" value="0.75;0.75">
<input type="hidden" name="__navigationButtonStack">
<input type="hidden" name="__startcontext" value="83::">
<input type="hidden" name="__acc" value="0">
<input type="hidden" name="__accoverride">
<input type="hidden" name="__pagemasterid" value="21">
<input type="hidden" name="__theme" value="MEC_GP">
<input type="hidden" name="script__enabled__" id="script__enabled__" value="1">
<script type="text/javascript">
if (document.getElementById) {
document.getElementById("script__enabled__").value = "1";
}
</script>
</div>
<div style="DISPLAY: none">
<link rel="stylesheet" type="text/css" href="https://hab.medefield.com/content/GP_CIT_Shell/LightBox/css/lightbox.min.css">
<script type="text/javascript" src="https://hab.medefield.com/content/jquery/core/jquery-1.4.4.min.js"></script>
<script type="text/javascript" src="https://hab.medefield.com/content/lib/jwplayer/jwplayer.js"></script>
<script type="text/javascript" src="https://hab.medefield.com/content/lib/html5media/html5media.min.js"></script>
<script src="https://hab.medefield.com/content/GP_CIT_Shell/LightBox/js/jquery-1.12.0.min.js"></script>
<script src="https://hab.medefield.com/content/GP_CIT_Shell/LightBox/js/lightbox.min.js"></script>
</div>
<div align="center"><br>
<div align="center">
<table style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 80%; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff" cellspacing="0" cellpadding="0" bgcolor="#ffffff" border="0">
<tbody>
<tr>
<td width="5%"></td>
<td width="90%" colspan="2">
<p></p>
<div class="mainHolder" align="center"> </div><!--<DIV align=left>--><br>
<table style="HEIGHT: 186px; WIDTH: 100%; BACKGROUND-COLOR: #ffffff" cellspacing="0" cellpadding="0" bgcolor="#ffffff" border="0">
<tbody>
<tr>
<td>
<div id="leftcolumn">
</div>
<div id="rightcolumn"><img src="http://c.peerview.com/assets/edel/service_logos/peerview.gif" alt="PeerView"></div>
<table cellspacing="0" cellpadding="0" width="100%" border="0">
<tbody>
<tr>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table><br>
<style>
#leftcolumn {
float: left;
PADDING-LEFT: 0px
}
#rightcolumn {
float: right;
PADDING-right: 0px
}
</style>
<table cellspacing="0" cellpadding="0" width="100%" border="0">
<tbody>
<tr>
<td>
<div style="PADDING-LEFT: 0px" align="center"> </div>
<div style="PADDING-LEFT: 0px" align="left">
<div class="survey_page_bg">
<div class="question">
<p></p>
<div id="info1_text" class="qtext">
<font size="4"><b>Complete the survey for $25 USD</b></font>
<p>
<b>Knowledge/Competence Assessment and Educational Needs Survey</b>
<br> You have been selected to participate in a brief survey designed to assess the current knowledge, competence, and educational needs of medical professionals who are actively involved in the diagnosis and
management of breast cancer.
</p>
<p> In appreciation for completing this survey, you will receive a <b>$25 USD honorarium</b>. </p>
<p>
<u>Questionnaire Length</u>: 7 questions (approx. 10 minutes).
</p>
</div>
<div id="info1_comment" class="comment">
<script>
function setCookieInfo() {}
</script>
</div>
</div>
<div class="question">
<br spellcheck="-1" class="temp-br">
<hr spellcheck="-1"><br spellcheck="-1">
<p spellcheck="-1" id="eb"></p>
<div id="q1_text" class="qtext">
<table>
<tbody>
<tr>
<td width="15" valign="top">1. </td>
<td> Based on the current FDA approval, the novel HER2-targeted therapy tucatinib is indicated for: </td>
</tr>
</tbody>
</table>
</div>
<!-- INPUT LAYOUT START -->
<div class="qianswersection">
<fieldset style="visibility: visible;" id="fieldset_q1">
<table cellspacing="0" summary="Answers of q1. Column number 1">
<thead class="confirmit-hidden">
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><input type="radio" name="q1" id="q1_1" value="1"></td>
<td><label for="q1_1" id="q1_1_label">Patients with advanced unresectable or metastatic HER2-positive breast cancer who have received no prior anti-HER2–based regimens in the metastatic setting</label></td>
</tr>
<tr>
<td><input type="radio" name="q1" id="q1_2" value="2"></td>
<td><label for="q1_2" id="q1_2_label">Patients with advanced unresectable or metastatic HER2-positive breast cancer, except those with brain metastases, who have received 1 prior anti-HER2–based regimen in the
metastatic setting</label></td>
</tr>
<tr>
<td><input type="radio" name="q1" id="q1_3" value="3"></td>
<td><label for="q1_3" id="q1_3_label">Patients with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who have received ≥1 prior anti-HER2–based regimen in
the metastatic setting</label></td>
</tr>
<tr>
<td><input type="radio" name="q1" id="q1_4" value="4"></td>
<td><label for="q1_4" id="q1_4_label">Patients with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who have received ≥2 prior anti-HER2–based regimens in
the metastatic setting</label></td>
</tr>
<tr>
<td><input type="radio" name="q1" id="q1_5" value="5"></td>
<td><label for="q1_5" id="q1_5_label">I am not sure</label></td>
</tr>
</tbody>
</table>
</fieldset>
</div><!-- INPUT LAYOUT END -->
<br spellcheck="-1" class="temp-br">
</div>
<div class="question">
<br spellcheck="-1" class="temp-br">
<hr spellcheck="-1"><br spellcheck="-1">
<p spellcheck="-1" id="eb"></p>
<div id="q2_text" class="qtext">
<table>
<tbody>
<tr>
<td width="15" valign="top">2. </td>
<td> The phase 3 NALA trial, which evaluated the irreversible pan-HER tyrosine kinase inhibitor neratinib plus capecitabine versus the reversible dual tyrosine kinase inhibitor lapatinib plus capecitabine, has
demonstrated significantly prolonged PFS with neratinib plus capecitabine in which of the following patient populations? </td>
</tr>
</tbody>
</table>
</div>
<!-- INPUT LAYOUT START -->
<div class="qianswersection">
<fieldset style="visibility: visible;" id="fieldset_q2">
<table cellspacing="0" summary="Answers of q2. Column number 1">
<thead class="confirmit-hidden">
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><input type="radio" name="q2" id="q2_1" value="1"></td>
<td><label for="q2_1" id="q2_1_label">No benefit was observed in any of the patient populations in which the combination was tested</label></td>
</tr>
<tr>
<td><input type="radio" name="q2" id="q2_2" value="2"></td>
<td><label for="q2_2" id="q2_2_label">Patients with previously untreated metastatic HER2-positive breast cancer</label></td>
</tr>
<tr>
<td><input type="radio" name="q2" id="q2_3" value="3"></td>
<td><label for="q2_3" id="q2_3_label">Patients with metastatic HER2-positive breast cancer that has progressed after 1 line of HER2-directed treatment</label></td>
</tr>
<tr>
<td><input type="radio" name="q2" id="q2_4" value="4"></td>
<td><label for="q2_4" id="q2_4_label">Patients with metastatic HER2-positive breast cancer that has progressed after at least 2 lines of HER2-directed treatment</label></td>
</tr>
<tr>
<td><input type="radio" name="q2" id="q2_5" value="5"></td>
<td><label for="q2_5" id="q2_5_label">I’m not sure</label></td>
</tr>
</tbody>
</table>
</fieldset>
</div><!-- INPUT LAYOUT END -->
<br spellcheck="-1" class="temp-br">
</div>
<div class="question">
<br spellcheck="-1" class="temp-br">
<hr spellcheck="-1"><br spellcheck="-1">
<p spellcheck="-1" id="eb"></p>
<div id="q3_text" class="qtext">
<table>
<tbody>
<tr>
<td width="15" valign="top">3. </td>
<td> Your patient is a 55-year-old woman with HER2-postive metastatic breast cancer who was previously treated with the combination of trastuzumab, pertuzumab, and docetaxel in the first-line setting and
trastuzumab emtansine in the second-line setting. Ten months later, she develops a persistent headache, and MRI reveals brain lesions with minimal edema. She is also found to have new liver lesions. Which
HER2-targeted therapy–based regimen would you recommend for this patient? </td>
</tr>
</tbody>
</table>
</div>
<!-- INPUT LAYOUT START -->
<div class="qianswersection">
<fieldset style="visibility: visible;" id="fieldset_q3">
<table cellspacing="0" summary="Answers of q3. Column number 1">
<thead class="confirmit-hidden">
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><input type="radio" name="q3" id="q3_1" value="1"></td>
<td><label for="q3_1" id="q3_1_label">Neratinib plus capecitabine</label></td>
</tr>
<tr>
<td><input type="radio" name="q3" id="q3_2" value="2"></td>
<td><label for="q3_2" id="q3_2_label">Tucatinib plus trastuzumab and capecitabine</label></td>
</tr>
<tr>
<td><input type="radio" name="q3" id="q3_3" value="3"></td>
<td><label for="q3_3" id="q3_3_label">Margetuximab plus capecitabine</label></td>
</tr>
<tr>
<td><input type="radio" name="q3" id="q3_4" value="4"></td>
<td><label for="q3_4" id="q3_4_label">Trastuzumab deruxtecan</label></td>
</tr>
<tr>
<td><input type="radio" name="q3" id="q3_5" value="5"></td>
<td><label for="q3_5" id="q3_5_label">Continue on trastuzumab emtansine</label></td>
</tr>
<tr>
<td><input type="radio" name="q3" id="q3_6" value="6"></td>
<td><label for="q3_6" id="q3_6_label">I’m not sure</label></td>
</tr>
</tbody>
</table>
</fieldset>
</div><!-- INPUT LAYOUT END -->
<br spellcheck="-1" class="temp-br">
</div>
<div class="question">
<br spellcheck="-1" class="temp-br">
<hr spellcheck="-1"><br spellcheck="-1">
<p spellcheck="-1" id="eb"></p>
<div id="q4_text" class="qtext">
<table>
<tbody>
<tr>
<td width="15" valign="top">4. </td>
<td> You are managing a 50-year-old patient with HER2-overexpressed breast cancer for whom you are considering treatment with the combination of neratinib and capecitabine. She expresses concern about the potential
for diarrhea as an adverse effect of the therapy and is asking for guidance on preventive approaches. Which of the following would you recommend as the best option for reducing the potential for development of
diarrhea in your patient? </td>
</tr>
</tbody>
</table>
</div>
<!-- INPUT LAYOUT START -->
<div class="qianswersection">
<fieldset style="visibility: visible;" id="fieldset_q4">
<table cellspacing="0" summary="Answers of q4. Column number 1">
<thead class="confirmit-hidden">
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><input type="radio" name="q4" id="q4_1" value="1"></td>
<td><label for="q4_1" id="q4_1_label">I would give the patient loperamide 4 mg three times a day as prophylaxis for the first two 4-week cycles and loperamide (≤16 mg/day) PRN after completion of loperamide
prophylaxis</label></td>
</tr>
<tr>
<td><input type="radio" name="q4" id="q4_2" value="2"></td>
<td><label for="q4_2" id="q4_2_label">I would give the patient budesonide 9 mg daily in the morning on days 1-28 of cycle 1 plus loperamide prophylaxis the first two 4-week cycles</label></td>
</tr>
<tr>
<td><input type="radio" name="q4" id="q4_3" value="3"></td>
<td><label for="q4_3" id="q4_3_label">I would give the patient colestipol 2 g orally twice daily for the first cycle plus loperamide 4 mg three times a day as prophylaxis for the first two 4-week cycles and
loperamide (≤16 mg/day) PRN after completion of loperamide prophylaxis</label></td>
</tr>
<tr>
<td><input type="radio" name="q4" id="q4_4" value="4"></td>
<td><label for="q4_4" id="q4_4_label">I would use the approach of escalating the doses of neratinib weekly (120 mg/day on days 1-7, 160 mg/days on days 8-14, and 240 mg/day thereafter) and give the patient
loperamide (≤16 mg/day) PRN</label></td>
</tr>
<tr>
<td><input type="radio" name="q4" id="q4_5" value="5"></td>
<td><label for="q4_5" id="q4_5_label">I’m not sure</label></td>
</tr>
</tbody>
</table>
</fieldset>
</div><!-- INPUT LAYOUT END -->
<br spellcheck="-1" class="temp-br">
</div>
<div class="question">
<br spellcheck="-1" class="temp-br">
<hr spellcheck="-1"><br spellcheck="-1">
<p spellcheck="-1" id="eb"></p>
<div id="q5_text" class="qtext">
<table>
<tbody>
<tr>
<td width="15" valign="top">5. </td>
<td> Your patient is a 58-year-old woman with HER2-positive metastatic breast cancer who received first-line therapy with docetaxel, trastuzumab, and pertuzumab, but 20 months later, she developed progression in
the liver, with a new 1-cm metastasis, as well as new lung metastases. Which of the following would you recommend for your patient next, taking into account the latest evidence and practice guidelines? </td>
</tr>
</tbody>
</table>
</div>
<!-- INPUT LAYOUT START -->
<div class="qianswersection">
<fieldset style="visibility: visible;" id="fieldset_q5">
<table cellspacing="0" summary="Answers of q5. Column number 1">
<thead class="confirmit-hidden">
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><input type="radio" name="q5" id="q5_1" value="1"></td>
<td><label for="q5_1" id="q5_1_label">Trastuzumab emtansine</label></td>
</tr>
<tr>
<td><input type="radio" name="q5" id="q5_2" value="2"></td>
<td><label for="q5_2" id="q5_2_label">Trastuzumab deruxtecan</label></td>
</tr>
<tr>
<td><input type="radio" name="q5" id="q5_3" value="3"></td>
<td><label for="q5_3" id="q5_3_label">Neratinib + capecitabine</label></td>
</tr>
<tr>
<td><input type="radio" name="q5" id="q5_4" value="4"></td>
<td><label for="q5_4" id="q5_4_label">Tucatinib plus trastuzumab and capecitabine</label></td>
</tr>
<tr>
<td><input type="radio" name="q5" id="q5_5" value="5"></td>
<td><label for="q5_5" id="q5_5_label">Margetuximab plus capecitabine</label></td>
</tr>
<tr>
<td><input type="radio" name="q5" id="q5_6" value="6"></td>
<td><label for="q5_6" id="q5_6_label">I’m not sure</label></td>
</tr>
</tbody>
</table>
</fieldset>
</div><!-- INPUT LAYOUT END -->
<br spellcheck="-1" class="temp-br">
</div>
<div class="question">
<br spellcheck="-1" class="temp-br">
<hr spellcheck="-1"><br spellcheck="-1" class="temp-br">
<p spellcheck="-1"></p>
<div id="q6_text" class="qtext">
<table>
<tbody>
<tr>
<td width="15" valign="top">6. </td>
<td> How often do you currently do the following? </td>
</tr>
</tbody>
</table>
</div>
<!-- INPUT LAYOUT START -->
<div class="qianswersection">
<fieldset style="visibility: visible;" id="fieldset_q6">
<table class="confirmit-grid qigcell" summary="Answers of q6">
<thead>
<tr id="yui_3_14_1_8_1640732973362_105">
<th id="q6_header0"></th>
<th id="q6_header1" class="qigscale" style="width:40px">Never<br>1</th>
<th id="q6_header2" class="qigscale" style="width:40px">Infrequently<br>2</th>
<th id="q6_header3" class="qigscale" style="width:40px">Sometimes<br>3</th>
<th id="q6_header4" class="qigscale" style="width:40px">Frequently<br>4</th>
<th id="q6_header5" class="qigscale" style="width:40px">Always<br>5</th>
<th id="q6_header6" class="qigscale" style="width:40px">N/A<br> </th>
</tr>
</thead>
<tbody>
<tr id="yui_3_14_1_8_1640732973362_106">
<th class="qiggridlabel">Consider the indications, unique characteristics and efficacy/safety profiles, and evidence-based use of different HER2-targeting agents when making individualized treatment
recommendations for patients with HER2-positive breast cancer</th>
<td headers="q6_header1" class="qiginput" id="yui_3_14_1_8_1640732973362_109"><input type="radio" name="q6_1" id="q6_1_1" value="1">
<div class="confirmit-hidden"><span>Consider the indications, unique characteristics and efficacy/safety profiles, and evidence-based use of different HER2-targeting agents when making individualized treatment
recommendations for patients with HER2-positive breast cancer</span><label for="q6_1_1">Never<br>1</label></div>
</td>
<td headers="q6_header2" class="qiginput" id="yui_3_14_1_8_1640732973362_114"><input type="radio" name="q6_1" id="q6_1_2" value="2">
<div class="confirmit-hidden"><label for="q6_1_2">Infrequently<br>2</label></div>
</td>
<td headers="q6_header3" class="qiginput" id="yui_3_14_1_8_1640732973362_119"><input type="radio" name="q6_1" id="q6_1_3" value="3">
<div class="confirmit-hidden"><label for="q6_1_3">Sometimes<br>3</label></div>
</td>
<td headers="q6_header4" class="qiginput" id="yui_3_14_1_8_1640732973362_124"><input type="radio" name="q6_1" id="q6_1_4" value="4">
<div class="confirmit-hidden"><label for="q6_1_4">Frequently<br>4</label></div>
</td>
<td headers="q6_header5" class="qiginput" id="yui_3_14_1_8_1640732973362_129"><input type="radio" name="q6_1" id="q6_1_5" value="5">
<div class="confirmit-hidden"><label for="q6_1_5">Always<br>5</label></div>
</td>
<td headers="q6_header6" class="qiginput" id="yui_3_14_1_8_1640732973362_134"><input type="radio" name="q6_1" id="q6_1_6" value="6">
<div class="confirmit-hidden"><label for="q6_1_6">N/A<br> </label></div>
</td>
</tr>
<tr>
<th class="qiggridlabel">Discuss the benefits and limitations different HER2-targeting therapies with patients with HER2-positive breast cancer</th>
<td headers="q6_header1" class="qiginput" id="yui_3_14_1_8_1640732973362_139"><input type="radio" name="q6_2" id="q6_2_1" value="1">
<div class="confirmit-hidden"><span>Discuss the benefits and limitations different HER2-targeting therapies with patients with HER2-positive breast cancer</span><label for="q6_2_1">Never<br>1</label></div>
</td>
<td headers="q6_header2" class="qiginput" id="yui_3_14_1_8_1640732973362_144"><input type="radio" name="q6_2" id="q6_2_2" value="2">
<div class="confirmit-hidden"><label for="q6_2_2">Infrequently<br>2</label></div>
</td>
<td headers="q6_header3" class="qiginput" id="yui_3_14_1_8_1640732973362_149"><input type="radio" name="q6_2" id="q6_2_3" value="3">
<div class="confirmit-hidden"><label for="q6_2_3">Sometimes<br>3</label></div>
</td>
<td headers="q6_header4" class="qiginput" id="yui_3_14_1_8_1640732973362_154"><input type="radio" name="q6_2" id="q6_2_4" value="4">
<div class="confirmit-hidden"><label for="q6_2_4">Frequently<br>4</label></div>
</td>
<td headers="q6_header5" class="qiginput" id="yui_3_14_1_8_1640732973362_159"><input type="radio" name="q6_2" id="q6_2_5" value="5">
<div class="confirmit-hidden"><label for="q6_2_5">Always<br>5</label></div>
</td>
<td headers="q6_header6" class="qiginput" id="yui_3_14_1_8_1640732973362_164"><input type="radio" name="q6_2" id="q6_2_6" value="6">
<div class="confirmit-hidden"><label for="q6_2_6">N/A<br> </label></div>
</td>
</tr>
<tr>
<th class="qiggridlabel">Discuss enrollment in clinical trials evaluating rational HER2-targeting agents or combination or sequential approaches with patients with HER2-positive metastatic breast cancer,
including patients in specific subgroups that have unmet needs (eg, patients with HER2-low status, HER2 mutations, brain metastases, among others)</th>
<td headers="q6_header1" class="qiginput" id="yui_3_14_1_8_1640732973362_169"><input type="radio" name="q6_3" id="q6_3_1" value="1">
<div class="confirmit-hidden"><span>Discuss enrollment in clinical trials evaluating rational HER2-targeting agents or combination or sequential approaches with patients with HER2-positive metastatic breast
cancer, including patients in specific subgroups that have unmet needs (eg, patients with HER2-low status, HER2 mutations, brain metastases, among others)</span><label for="q6_3_1">Never<br>1</label></div>
</td>
<td headers="q6_header2" class="qiginput" id="yui_3_14_1_8_1640732973362_174"><input type="radio" name="q6_3" id="q6_3_2" value="2">
<div class="confirmit-hidden"><label for="q6_3_2">Infrequently<br>2</label></div>
</td>
<td headers="q6_header3" class="qiginput" id="yui_3_14_1_8_1640732973362_179"><input type="radio" name="q6_3" id="q6_3_3" value="3">
<div class="confirmit-hidden"><label for="q6_3_3">Sometimes<br>3</label></div>
</td>
<td headers="q6_header4" class="qiginput" id="yui_3_14_1_8_1640732973362_184"><input type="radio" name="q6_3" id="q6_3_4" value="4">
<div class="confirmit-hidden"><label for="q6_3_4">Frequently<br>4</label></div>
</td>
<td headers="q6_header5" class="qiginput" id="yui_3_14_1_8_1640732973362_189"><input type="radio" name="q6_3" id="q6_3_5" value="5">
<div class="confirmit-hidden"><label for="q6_3_5">Always<br>5</label></div>
</td>
<td headers="q6_header6" class="qiginput" id="yui_3_14_1_8_1640732973362_194"><input type="radio" name="q6_3" id="q6_3_6" value="6">
<div class="confirmit-hidden"><label for="q6_3_6">N/A<br> </label></div>
</td>
</tr>
<tr>
<th class="qiggridlabel">Test patients with breast cancer for HER2 status (including HER2 low and HER2 mutations) to determine their candidacy for HER2-targeting therapies</th>
<td headers="q6_header1" class="qiginput" id="yui_3_14_1_8_1640732973362_199"><input type="radio" name="q6_4" id="q6_4_1" value="1">
<div class="confirmit-hidden"><span>Test patients with breast cancer for HER2 status (including HER2 low and HER2 mutations) to determine their candidacy for HER2-targeting therapies</span><label
for="q6_4_1">Never<br>1</label></div>
</td>
<td headers="q6_header2" class="qiginput" id="yui_3_14_1_8_1640732973362_204"><input type="radio" name="q6_4" id="q6_4_2" value="2">
<div class="confirmit-hidden"><label for="q6_4_2">Infrequently<br>2</label></div>
</td>
<td headers="q6_header3" class="qiginput" id="yui_3_14_1_8_1640732973362_209"><input type="radio" name="q6_4" id="q6_4_3" value="3">
<div class="confirmit-hidden"><label for="q6_4_3">Sometimes<br>3</label></div>
</td>
<td headers="q6_header4" class="qiginput" id="yui_3_14_1_8_1640732973362_214"><input type="radio" name="q6_4" id="q6_4_4" value="4">
<div class="confirmit-hidden"><label for="q6_4_4">Frequently<br>4</label></div>
</td>
<td headers="q6_header5" class="qiginput" id="yui_3_14_1_8_1640732973362_219"><input type="radio" name="q6_4" id="q6_4_5" value="5">
<div class="confirmit-hidden"><label for="q6_4_5">Always<br>5</label></div>
</td>
<td headers="q6_header6" class="qiginput" id="yui_3_14_1_8_1640732973362_224"><input type="radio" name="q6_4" id="q6_4_6" value="6">
<div class="confirmit-hidden"><label for="q6_4_6">N/A<br> </label></div>
</td>
</tr>
<tr>
<th class="qiggridlabel">Use dose escalation to manage diarrhea in patients with HER2-positive breast cancer who are being treated with neratinib</th>
<td headers="q6_header1" class="qiginput" id="yui_3_14_1_8_1640732973362_229"><input type="radio" name="q6_5" id="q6_5_1" value="1">
<div class="confirmit-hidden"><span>Use dose escalation to manage diarrhea in patients with HER2-positive breast cancer who are being treated with neratinib</span><label for="q6_5_1">Never<br>1</label></div>
</td>
<td headers="q6_header2" class="qiginput" id="yui_3_14_1_8_1640732973362_234"><input type="radio" name="q6_5" id="q6_5_2" value="2">
<div class="confirmit-hidden"><label for="q6_5_2">Infrequently<br>2</label></div>
</td>
<td headers="q6_header3" class="qiginput" id="yui_3_14_1_8_1640732973362_239"><input type="radio" name="q6_5" id="q6_5_3" value="3">
<div class="confirmit-hidden"><label for="q6_5_3">Sometimes<br>3</label></div>
</td>
<td headers="q6_header4" class="qiginput" id="yui_3_14_1_8_1640732973362_244"><input type="radio" name="q6_5" id="q6_5_4" value="4">
<div class="confirmit-hidden"><label for="q6_5_4">Frequently<br>4</label></div>
</td>
<td headers="q6_header5" class="qiginput" id="yui_3_14_1_8_1640732973362_249"><input type="radio" name="q6_5" id="q6_5_5" value="5">
<div class="confirmit-hidden"><label for="q6_5_5">Always<br>5</label></div>
</td>
<td headers="q6_header6" class="qiginput" id="yui_3_14_1_8_1640732973362_254"><input type="radio" name="q6_5" id="q6_5_6" value="6">
<div class="confirmit-hidden"><label for="q6_5_6">N/A<br> </label></div>
</td>
</tr>
<tr>
<th class="qiggridlabel">Monitor patients with HER2-postive breast cancer being treated with different HER2-targeted therapies according to relevant warnings/precautions about potential adverse events</th>
<td headers="q6_header1" class="qiginput" id="yui_3_14_1_8_1640732973362_259"><input type="radio" name="q6_6" id="q6_6_1" value="1">
<div class="confirmit-hidden"><span>Monitor patients with HER2-postive breast cancer being treated with different HER2-targeted therapies according to relevant warnings/precautions about potential adverse
events</span><label for="q6_6_1">Never<br>1</label></div>
</td>
<td headers="q6_header2" class="qiginput" id="yui_3_14_1_8_1640732973362_264"><input type="radio" name="q6_6" id="q6_6_2" value="2">
<div class="confirmit-hidden"><label for="q6_6_2">Infrequently<br>2</label></div>
</td>
<td headers="q6_header3" class="qiginput" id="yui_3_14_1_8_1640732973362_269"><input type="radio" name="q6_6" id="q6_6_3" value="3">
<div class="confirmit-hidden"><label for="q6_6_3">Sometimes<br>3</label></div>
</td>
<td headers="q6_header4" class="qiginput" id="yui_3_14_1_8_1640732973362_274"><input type="radio" name="q6_6" id="q6_6_4" value="4">
<div class="confirmit-hidden"><label for="q6_6_4">Frequently<br>4</label></div>
</td>
<td headers="q6_header5" class="qiginput" id="yui_3_14_1_8_1640732973362_279"><input type="radio" name="q6_6" id="q6_6_5" value="5">
<div class="confirmit-hidden"><label for="q6_6_5">Always<br>5</label></div>
</td>
<td headers="q6_header6" class="qiginput" id="yui_3_14_1_8_1640732973362_284"><input type="radio" name="q6_6" id="q6_6_6" value="6">
<div class="confirmit-hidden"><label for="q6_6_6">N/A<br> </label></div>
</td>
</tr>
<tr>
<th class="qiggridlabel">Provide education, guidance, and resources to patients with HER2-positive breast cancer about HER2-targeted therapy, including efficacy and treatment-related adverse events associated
with HER2-targeting therapies</th>
<td headers="q6_header1" class="qiginput" id="yui_3_14_1_8_1640732973362_289"><input type="radio" name="q6_7" id="q6_7_1" value="1">
<div class="confirmit-hidden"><span>Provide education, guidance, and resources to patients with HER2-positive breast cancer about HER2-targeted therapy, including efficacy and treatment-related adverse events
associated with HER2-targeting therapies</span><label for="q6_7_1">Never<br>1</label></div>
</td>
<td headers="q6_header2" class="qiginput" id="yui_3_14_1_8_1640732973362_294"><input type="radio" name="q6_7" id="q6_7_2" value="2">
<div class="confirmit-hidden"><label for="q6_7_2">Infrequently<br>2</label></div>
</td>
<td headers="q6_header3" class="qiginput" id="yui_3_14_1_8_1640732973362_299"><input type="radio" name="q6_7" id="q6_7_3" value="3">
<div class="confirmit-hidden"><label for="q6_7_3">Sometimes<br>3</label></div>
</td>
<td headers="q6_header4" class="qiginput" id="yui_3_14_1_8_1640732973362_304"><input type="radio" name="q6_7" id="q6_7_4" value="4">
<div class="confirmit-hidden"><label for="q6_7_4">Frequently<br>4</label></div>
</td>
<td headers="q6_header5" class="qiginput" id="yui_3_14_1_8_1640732973362_309"><input type="radio" name="q6_7" id="q6_7_5" value="5">
<div class="confirmit-hidden"><label for="q6_7_5">Always<br>5</label></div>
</td>
<td headers="q6_header6" class="qiginput" id="yui_3_14_1_8_1640732973362_314"><input type="radio" name="q6_7" id="q6_7_6" value="6">
<div class="confirmit-hidden"><label for="q6_7_6">N/A<br> </label></div>
</td>
</tr>
</tbody>
</table>
</fieldset>
</div><!-- INPUT LAYOUT END -->
<br spellcheck="-1" class="temp-br"><br spellcheck="-1" class="temp-br">
<style spellcheck="-1">
.confirmit-abtn-label {
text-align: center;
}
</style>
</div>
<div class="question">
<br spellcheck="-1" class="temp-br">
<hr spellcheck="-1"><br spellcheck="-1">
<p spellcheck="-1" id="eb"></p>
<div id="q7_text" class="qtext"><label for="q7">
<table>
<tbody>
<tr>
<td width="15" valign="top">7. </td>
<td> Please submit at least one question, challenging case scenario, or barrier related to breast cancer that you would like an expert in the field to address as part of an upcoming educational activity: </td>
</tr>
</tbody>
</table>
</label></div>
<div id="q7_comment" class="comment"><b><u>Note</u>: To receive your honorarium for participating in the survey, this field must be completed.</b>
<br><br>
</div>
<!-- INPUT LAYOUT START -->
<div class="qianswersection">
<fieldset id="fieldset_q7" style="visibility: visible;">
<table cellspacing="0" summary="Answers of q7. Column number 1">
<thead class="confirmit-hidden">
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><textarea cols="50" rows="5" name="q7" class="confirmit-textarea qiopentext" id="q7"></textarea>
</td>
</tr>
</tbody>
</table>
</fieldset>
</div><!-- INPUT LAYOUT END -->
<br spellcheck="-1" class="temp-br">
</div>
<div class="question">
<p></p>
<div id="i60_text" class="qtext">
<center>
<br><br><br>
<input type="submit" name="__fwd" value=" Continue " style="font:x-small verdana;background-color:lightsteelblue;color:#324E8C;border:1px solid steelblue;">
</center>
</div>
</div>
</div>
</div>
<div style="PADDING-LEFT: 0px; DISPLAY: none" align="left">
<div><span class="confirmit-fwdfirstnav-next"><input type="submit" onclick=" if(typeof wix=='object') {wix.nav(event, 'p615098493');} " class="confirmit-nav" id="forwardbutton" name="__fwd" style="float:left"
value="Next"></span><span class="confirmit-fwdfirstnav-prev"><input type="submit" onclick=" if(typeof wix=='object') {wix.back(event, 'p615098493');} " class="confirmit-nav" id="backbutton" name="__bck"
style="float:right" value="Back"></span>
<div class="clear_b"></div>
</div>
</div>
</td>
</tr>
</tbody>
</table>
<div style="FONT-SIZE: small; TEXT-ALIGN: left; PADDING-LEFT: 0px"><a class="TermCon" href="http://gpcms.habcommunity.com/terms.php?site_id=28" target="_blank">Terms and Conditions</a>
<!--<A href="http://www.peerviewpress.com/privacy" target=_blank>Privacy Policy</A> --><a class="Help" href="mailto:techhelp@peerviewpress.com ?subject=Ref: p615098493_(MV)&body=Please keep the subject text when sending your email" target="_blank">Help </a><br>
<font color="#666666"></font>
</div>
<div></div>
<p></p>
<p> </p>
<div></div>
<div></div>
</td>
<td width="5%"></td>
</tr>
<tr>
<td width="5%"></td>
<td width="90%" colspan="2">
<hr class="bottomBar" color="#808080" width="100%">
</td>
<td width="5%"></td>
</tr>
<tr>
<td width="5%"></td>
<td valign="bottom" width="60%" align="center">
<p align="left">
<!--<a style="text-decoration: none" class="helplink" href="mailto:?subject=Ref:<em>NO RESPONSE</em>/p615098493/300&body=Please keep the subject text when sending your email"><em><font color="#808080" size="-1" face="arial">Help / Pour assistance / Hilfe / Per assistenza / Ayuda</font></em></a>-->
</p>
<p></p>
</td>
<td valign="middle" width="30%" align="right"><!----></td>
<td width="5%"></td>
</tr>
</tbody>
</table>
<div></div>
<div align="center"><input id="mQID" alt="" size="25" type="hidden" name="mQID"></div>
<script type="text/javascript">
function disableSelection(target) {
if (typeof target.onselectstart != "undefined") //IE route
target.onselectstart = function() {
return false
}
else if (typeof target.style.MozUserSelect != "undefined") //Firefox route
target.style.MozUserSelect = "none"
else //For the others
target.onmousedown = function() {
return false
}
target.style.cursor = "default"
}
disableSelection(document.body);
</script>
<style type="text/css" media="print">
BODY {
display: none;
visibility: hidden;
}
</style>
<script language="JavaScript">
<!--
var message = "Sorry, that function is disabled.";
function click(e) {
if (document.all) {
if (event.button == 2) {
alert(message);
return false;
}
}
if (document.layers) {
if (e.which == 3) {
alert(message);
return false;
}
}
}
if (document.layers) document.captureEvents(Event.MOUSEDOWN);
document.onmousedown = click;
//
-->
</script>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<script type="text/javascript">
function disableSelection(target) {
if (typeof target.onselectstart !=
"undefined") //IE route target.onselectstart=function(){return false} else if (typeof target.style.MozUserSelect!="undefined" ) //Firefox route target.style.MozUserSelect="none" else //For the others target.onmousedown=function(){return false} target.style.cursor="default" } //disableSelection(document.body);
</script>
<!--Show or Hide term & Condition, Help-->
<style type="text/css">
.TermCon {
display: none;
}
</style>
</div>
</div>
<div>
<input type="hidden" name="l" value="9">
</div>
<div class="poweredby"><a href="http://www.confirmit.com" target="_blank">Powered by Confirmit</a></div>
</form>Text Content
Complete the survey for $25 USD Knowledge/Competence Assessment and Educational Needs Survey You have been selected to participate in a brief survey designed to assess the current knowledge, competence, and educational needs of medical professionals who are actively involved in the diagnosis and management of breast cancer. In appreciation for completing this survey, you will receive a $25 USD honorarium. Questionnaire Length: 7 questions (approx. 10 minutes). -------------------------------------------------------------------------------- 1. Based on the current FDA approval, the novel HER2-targeted therapy tucatinib is indicated for: Patients with advanced unresectable or metastatic HER2-positive breast cancer who have received no prior anti-HER2–based regimens in the metastatic setting Patients with advanced unresectable or metastatic HER2-positive breast cancer, except those with brain metastases, who have received 1 prior anti-HER2–based regimen in the metastatic setting Patients with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who have received ≥1 prior anti-HER2–based regimen in the metastatic setting Patients with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who have received ≥2 prior anti-HER2–based regimens in the metastatic setting I am not sure -------------------------------------------------------------------------------- 2. The phase 3 NALA trial, which evaluated the irreversible pan-HER tyrosine kinase inhibitor neratinib plus capecitabine versus the reversible dual tyrosine kinase inhibitor lapatinib plus capecitabine, has demonstrated significantly prolonged PFS with neratinib plus capecitabine in which of the following patient populations? No benefit was observed in any of the patient populations in which the combination was tested Patients with previously untreated metastatic HER2-positive breast cancer Patients with metastatic HER2-positive breast cancer that has progressed after 1 line of HER2-directed treatment Patients with metastatic HER2-positive breast cancer that has progressed after at least 2 lines of HER2-directed treatment I’m not sure -------------------------------------------------------------------------------- 3. Your patient is a 55-year-old woman with HER2-postive metastatic breast cancer who was previously treated with the combination of trastuzumab, pertuzumab, and docetaxel in the first-line setting and trastuzumab emtansine in the second-line setting. Ten months later, she develops a persistent headache, and MRI reveals brain lesions with minimal edema. She is also found to have new liver lesions. Which HER2-targeted therapy–based regimen would you recommend for this patient? Neratinib plus capecitabine Tucatinib plus trastuzumab and capecitabine Margetuximab plus capecitabine Trastuzumab deruxtecan Continue on trastuzumab emtansine I’m not sure -------------------------------------------------------------------------------- 4. You are managing a 50-year-old patient with HER2-overexpressed breast cancer for whom you are considering treatment with the combination of neratinib and capecitabine. She expresses concern about the potential for diarrhea as an adverse effect of the therapy and is asking for guidance on preventive approaches. Which of the following would you recommend as the best option for reducing the potential for development of diarrhea in your patient? I would give the patient loperamide 4 mg three times a day as prophylaxis for the first two 4-week cycles and loperamide (≤16 mg/day) PRN after completion of loperamide prophylaxis I would give the patient budesonide 9 mg daily in the morning on days 1-28 of cycle 1 plus loperamide prophylaxis the first two 4-week cycles I would give the patient colestipol 2 g orally twice daily for the first cycle plus loperamide 4 mg three times a day as prophylaxis for the first two 4-week cycles and loperamide (≤16 mg/day) PRN after completion of loperamide prophylaxis I would use the approach of escalating the doses of neratinib weekly (120 mg/day on days 1-7, 160 mg/days on days 8-14, and 240 mg/day thereafter) and give the patient loperamide (≤16 mg/day) PRN I’m not sure -------------------------------------------------------------------------------- 5. Your patient is a 58-year-old woman with HER2-positive metastatic breast cancer who received first-line therapy with docetaxel, trastuzumab, and pertuzumab, but 20 months later, she developed progression in the liver, with a new 1-cm metastasis, as well as new lung metastases. Which of the following would you recommend for your patient next, taking into account the latest evidence and practice guidelines? Trastuzumab emtansine Trastuzumab deruxtecan Neratinib + capecitabine Tucatinib plus trastuzumab and capecitabine Margetuximab plus capecitabine I’m not sure -------------------------------------------------------------------------------- 6. How often do you currently do the following? Never 1 Infrequently 2 Sometimes 3 Frequently 4 Always 5 N/A Consider the indications, unique characteristics and efficacy/safety profiles, and evidence-based use of different HER2-targeting agents when making individualized treatment recommendations for patients with HER2-positive breast cancer Consider the indications, unique characteristics and efficacy/safety profiles, and evidence-based use of different HER2-targeting agents when making individualized treatment recommendations for patients with HER2-positive breast cancerNever 1 Infrequently 2 Sometimes 3 Frequently 4 Always 5 N/A Discuss the benefits and limitations different HER2-targeting therapies with patients with HER2-positive breast cancer Discuss the benefits and limitations different HER2-targeting therapies with patients with HER2-positive breast cancerNever 1 Infrequently 2 Sometimes 3 Frequently 4 Always 5 N/A Discuss enrollment in clinical trials evaluating rational HER2-targeting agents or combination or sequential approaches with patients with HER2-positive metastatic breast cancer, including patients in specific subgroups that have unmet needs (eg, patients with HER2-low status, HER2 mutations, brain metastases, among others) Discuss enrollment in clinical trials evaluating rational HER2-targeting agents or combination or sequential approaches with patients with HER2-positive metastatic breast cancer, including patients in specific subgroups that have unmet needs (eg, patients with HER2-low status, HER2 mutations, brain metastases, among others)Never 1 Infrequently 2 Sometimes 3 Frequently 4 Always 5 N/A Test patients with breast cancer for HER2 status (including HER2 low and HER2 mutations) to determine their candidacy for HER2-targeting therapies Test patients with breast cancer for HER2 status (including HER2 low and HER2 mutations) to determine their candidacy for HER2-targeting therapiesNever 1 Infrequently 2 Sometimes 3 Frequently 4 Always 5 N/A Use dose escalation to manage diarrhea in patients with HER2-positive breast cancer who are being treated with neratinib Use dose escalation to manage diarrhea in patients with HER2-positive breast cancer who are being treated with neratinibNever 1 Infrequently 2 Sometimes 3 Frequently 4 Always 5 N/A Monitor patients with HER2-postive breast cancer being treated with different HER2-targeted therapies according to relevant warnings/precautions about potential adverse events Monitor patients with HER2-postive breast cancer being treated with different HER2-targeted therapies according to relevant warnings/precautions about potential adverse eventsNever 1 Infrequently 2 Sometimes 3 Frequently 4 Always 5 N/A Provide education, guidance, and resources to patients with HER2-positive breast cancer about HER2-targeted therapy, including efficacy and treatment-related adverse events associated with HER2-targeting therapies Provide education, guidance, and resources to patients with HER2-positive breast cancer about HER2-targeted therapy, including efficacy and treatment-related adverse events associated with HER2-targeting therapiesNever 1 Infrequently 2 Sometimes 3 Frequently 4 Always 5 N/A -------------------------------------------------------------------------------- 7. Please submit at least one question, challenging case scenario, or barrier related to breast cancer that you would like an expert in the field to address as part of an upcoming educational activity: Note: To receive your honorarium for participating in the survey, this field must be completed. Terms and Conditions Help -------------------------------------------------------------------------------- Powered by Confirmit